Marketing Application Update, Acquisitions, Collaborations, FDA Approvals, and Structural Changes - Research Reports on Gilead, BD, Pfizer, AbbVie and Novartis

NEW YORK, October 10, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Gilead Sciences Inc. (NASDAQ: GILD), Becton, Dickinson and Company (NYSE: BDX), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV) and Novartis AG (NYSE: NVS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7083-100free.

--
Gilead Sciences Inc. Research Reports
On September 26, 2014, Gilead Sciences Inc. (Gilead) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company's Marketing Authorization Application (MAA) for Harvoni, an investigational once-daily tablet for the Treatment of Chronic Hepatitis C Infection in Adults. The CHMP judgment was formed on account of an accelerated review procedure, and was also supported by data from three Phase III studies (ION-1, ION-2 and ION-3). According to Gilead, the CHMP's approval will be followed by a review by the European Commission, which has the authority to sanction medicines for use in the 28 countries of the European Union. The full research reports on Gilead are available to download free of charge at:

http://www.analystsreview.com/Oct-10-2014/GILD/report.pdf

--
Becton, Dickinson and Company Research Reports
On October 5, 2014, Becton, Dickinson and Company (BD) signed a definitive agreement under which the Company will acquire CareFusion in a cash and stock deal, aggregating $12.2 billion. As per the agreement, CareFusion shareholders will receive $49.00 in cash and 0.0777 of a share of BD for each share of CareFusion, or a total of $58.00 per CareFusion share based on BD's closing price as of October 3, 2014. The acquisition is expected to close in H1 2015, after which BD shareholders will own approximately 92% interest of the amalgamated company, while the remaining will be owned by CareFusion shareholders. The combination of the two companies' complementary product portfolios will offer integrated medication management solutions and smart devices, from drug preparation in the pharmacy, to dispensing on the hospital floor, administration to the patient, and subsequent monitoring. The full research reports on BD are available to download free of charge at:

http://www.analystsreview.com/Oct-10-2014/BDX/report.pdf

--
Pfizer Inc. Research Reports
On September 29, 2014, Pfizer Inc. (Pfizer) announced its collaboration with Kyowa Hakko Kirin to explore an Immuno-Oncology Combination Study. As per Pfizer, the partnership will investigate the therapeutic potential of the combination of Pfizer's PF-05082566, an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival, with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab, which suppresses some of the immune cells that shield the tumor from the immune system, in a Phase Ib clinical study evaluating the safety and tolerability of the combination in patients with solid tumors. Dr. Mace Rothenberg, SVP of Clinical Development and Medical Affairs and Chief Medical Officer for Pfizer Oncology said, "Our collaboration with Kyowa Hakko Kirin provides an additional important partnership opportunity to explore the potential of 4-1BB as part of a novel immunotherapy combination regimen." The full research reports on Pfizer are available to download free of charge at:

http://www.analystsreview.com/Oct-10-2014/PFE/report.pdf

--
AbbVie Inc. Research Reports
On October 6, 2014, AbbVie Inc. (AbbVie) announced that it has received FDA approval for the extension of the Humira indication for moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) to reduce signs and symptoms in patients ages 2 and older. As per the Company, Humira is used to decrease the traces and symptoms of moderate to severe: rheumatoid arthritis, JIA, Psoriatic arthritis, Ankylosing spondylitis, Ankylosing spondylitis and others. The Company added that the drug will be available to patients ages 2 and older living with polyarticular JIA with the dose based on patient weight. It is presently available in the form of a 10 mg pre-filled syringe, 20 mg pre-filled syringe, 40 mg pre-filled syringe and 40 mg HUMIRA auto-injector pen. The full research reports on AbbVie are available to download free of charge at:

http://www.analystsreview.com/Oct-10-2014/ABBV/report.pdf

--
Novartis AG Research Reports
On October 8, 2014, Novartis AG (Novartis) reported that after the completion of its portfolio transactions with GlaxoSmithKline (GSK) and Eli Lilly and Company, in H1 2015, George Gunn, Brian McNamara and Andrin Oswald will depart from the Executive Committee of Novartis. The aforementioned individuals are currently working at the center of the transaction. George Gunn, Division Head, Novartis Animal Health, will retire from Novartis in July 2015. Brian McNamara, Division Head, Novartis OTC, will changeover to GSK as Head of Americas and Europe for the consumer health businesses, and Andrin Oswald, Division Head, Novartis Vaccines, will be leaving Novartis to pursue other opportunities. The full research reports on Novartis are available to download free of charge at:

http://www.analystsreview.com/Oct-10-2014/NVS/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review